Is ocugen’s stock overvalued?
Only 3.65% of the stock of Ocugen is held by insiders. Only 28.45% of the stock of Ocugen is held by institutions. Earnings for Ocugen are expected to grow in the coming year, from ($0.30) to $0.30 per share. Ocugen has a P/B Ratio of 40.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Why did ocugen stock skyrocket on Tuesday?
Shares of Ocugen (NASDAQ: OCGN) had skyrocketed by 19.1% as of 11:15 a.m. ET on Tuesday. The huge gain came after the company announced that the Food and Drug Administration (FDA) had lifted the clinical hold on its investigational new drug (IND) application for COVID-19 vaccine Covaxin. Ocugen's announcement came after the market closed on Friday.
Should you hold ocugen (ocgn) stock?
The consensus among Wall Street equities research analysts is that investors should "hold" Ocugen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OCGN, but not buy additional shares or sell existing shares. View analyst ratings for Ocugen or view top-rated stocks.
When is ocugen's next quarterly earnings announcement?
Ocugen is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022. View our earnings forecast for Ocugen. How were Ocugen's earnings last quarter? Ocugen, Inc. (NASDAQ:OCGN) issued its quarterly earnings data on Tuesday, November, 9th.
Why is Ocugen stock skyrocketed today?
Shares of the biotech company skyrocketed in early 2021 after it announced an agreement with India-based Bharat Biotech. The deal stipulated that Ocugen would hold the right to commercialize the Covaxin coronavirus vaccine, which was originally developed by Bharat Biotech, in the U.S. and Canada.
Is Ocugen stock expected to rise?
Stock Price Forecast The 5 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 7.00, with a high estimate of 15.00 and a low estimate of 3.50. The median estimate represents a +224.07% increase from the last price of 2.16.
What is happening to Ocugen?
Ocugen abandoned its pursuit of a U.S. EUA for Covaxin in immunizing adults last year. The FDA told the company in June 2021 that it should instead follow the standard path to full approval of the vaccine in adults. Image source: Getty Images.
Is Ocugen a good stock to buy?
Ocugen is too risky a stock to invest in today, even with the positive news it received of late. Investors are better off looking at other growth stocks that are safer, long-term buys. David Jagielski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.
What is the target price for Ocugen?
Stock Price TargetsHigh$15.00Median$5.50Low$3.50Average$7.38Current Price$2.2100
What is the future of OCGN?
Based on our forecasts, a long-term increase is expected, the "OCGN" stock price prognosis for 2027-05-21 is 5.859 USD. With a 5-year investment, the revenue is expected to be around +145.15%. Your current $100 investment may be up to $245.15 in 2027.
Will Ocugen vaccine get approved?
Ocugen gets FDA approval to resume COVID vaccine trial.
Why Ocugen stock drop today?
There are two primary underlying reasons behind Ocugen's steep sell-off over the last two months, with shares plunging more than 70%. Most importantly, the company still hasn't secured an authorization or approval in the U.S. or Canada for COVID-19 vaccine Covaxin.
Did OCGN reverse split?
The split for OCGN took place on September 30, 2019. This was a 1 for 60 reverse split, meaning for each 60 shares of OCGN owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 16.6666666666667 share position following the split.
Who bought OCGN stock?
Top 10 Owners of Ocugen IncStockholderStakeShares bought / soldBlackRock Fund Advisors4.85%-747,441The Vanguard Group, Inc.4.84%+332,517JPMorgan Asset Management (UK) Lt...1.44%-89,678Southpoint Capital Advisors LP1.39%+1,645,2906 more rows
Should I buy or sell Ocugen stock right now?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last year. There are currently 2 hold ratings and 3 buy rati...
What is Ocugen's stock price forecast for 2022?
5 brokers have issued 12 month price targets for Ocugen's shares. Their forecasts range from $3.50 to $15.00. On average, they expect Ocugen's stoc...
How has Ocugen's stock price performed in 2022?
Ocugen's stock was trading at $4.55 on January 1st, 2022. Since then, OCGN stock has decreased by 50.1% and is now trading at $2.27. View the best...
When is Ocugen's next earnings date?
Ocugen is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022. View our earnings forecast for Ocugen .
How were Ocugen's earnings last quarter?
Ocugen, Inc. (NASDAQ:OCGN) released its earnings results on Friday, May, 6th. The company reported ($0.09) earnings per share (EPS) for the quarter...
Who are Ocugen's key executives?
Ocugen's management team includes the following people: Dr. Shankar Musunuri M.B.A. , MBA, Ph.D., Co-Founder, Chairman & CEO (Age 58, Pay $780.6...
Who are some of Ocugen's key competitors?
Some companies that are related to Ocugen include BioCryst Pharmaceuticals (BCRX) , Exscientia (EXAI) , Relay Therapeutics (RLAY) , Twist Biosc...
What other stocks do shareholders of Ocugen own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Ocugen investors own include Onconova Therapeutics (ONTX)...
What is Ocugen's stock symbol?
Ocugen trades on the NASDAQ under the ticker symbol "OCGN."
Who bought Ocugen stock?
What is the hold rating on Ocugen?
OCGN stock was bought by a variety of institutional investors in the last quarter, including Golden Green Inc.. Company insiders that have bought Ocugen stock in the last two years include Howard C Draft, Junge Zhang, Kirsten Castillo, Sanjay Subramanian, and Shankar Musunuri.
Is Ocugen a hold?
A hold rating indicates that analysts believe investors should maintain any existing positions they have in OCGN, but not buy additional shares or sell existing shares.
What Happened With OCGN Stock
Wall Street analysts have given Ocugen a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ocugen wasn't one of them.
Why It Matters
In a news release, Ocugen said that its India-based partner Bharat Biotech achieved positive results from a Phase 2 clinical trial of Covaxin that was given to people ages 12-64.
What happened
Ocugen and its stock have been on a rollercoaster ride over the last year. Ocugen’s stock price is up 63% in the last year, but has slumped 42% in the past six months as approval of Covaxin in North America has been repeatedly delayed.
So what
Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 22.1% higher as of 11:28 a.m. EDT on Tuesday. The big jump came as investors anxiously awaited a meeting today of the World Health Organization's technical advisory committee.
Now what
If the World Health Organization grants EUL to Covaxin, it would pave the way for the vaccine to be distributed to countries that participate in the COVAX Facility. That would certainly be good news for Bharat Biotech.
The Motley Fool
There's a much more important pending decision that really matters for Ocugen -- Health Canada's review of the company's rolling regulatory submission for Covaxin. If this decision is favorable, Ocugen investors would have a legitimate reason to celebrate.
What happened
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
So what
Shares of Ocugen (NASDAQ: OCGN) had skyrocketed by 19.1% as of 11:15 a.m. ET on Tuesday. The huge gain came after the company announced that the Food and Drug Administration (FDA) had lifted the clinical hold on its investigational new drug (IND) application for COVID-19 vaccine Covaxin.
Now what
Ocugen's announcement came after the market closed on Friday. Since the stock market was closed on Monday for Presidents' Day, investors had to wait for the biotech stock to soar.
The Motley Fool
Ocugen could have more details to share related to its Covaxin efforts later on Friday, when it's scheduled to host a conference call to discuss its fourth-quarter and full-year results, and provide a business update.
Key Points
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
What happened
Investors expecting a sustained bullish rally following an approval from the WHO were left disappointed.
So what
Shares of Ocugen ( OCGN -2.40% ) are giving up ground in Wednesday's trading. The biotech stock was down roughly 12% in the daily session as of 11 a.m. EDT.
NASDAQ: OCGN
Ocugen stock had made gains in premarket trading following the announcement that Covaxin had received EUL approval, but shares retreated at the opening of the normal daily session. Even with the pullback, Ocugen is up roughly 99% over the past three months and 655% year to date.
Now what
Investors appear to have been banking on the WHO's decision to drive the company's share price even higher. EUL status will make it easier for countries to import and administer the vaccine. And it means that people who have received it will be subject to fewer travel and quarantining restrictions in many countries.
Premium Investing Services
Receiving EUL approval for Covaxin represents a significant milestone for Bharat Biotech and Ocugen, but it looks like expectations were already too high to power more gains for the latter company's stock. After the recent pullback, Ocugen now has a market capitalization of roughly $2.7 billion.